Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin

• References

• 1 Hérault JP, Bernat A, Roye F. et al. Pharmacokinetics of new synthetic heparin mimetics. Thomb Haemost 2002; 87: 985-989.
• 2 Harenberg J, Jörg I, Vukojevic Y. et al. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observation from the van Gogh trials. Eur J Clin Pharmacol 2008; 64: 555-563.
• 3 Veyrat-Follet C, Vivier N, Trellu M. et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost. 2009 in press.
• 4 Gouin-Thibault I, Dingler E, Maris A. et al. In vitro interaction of the pentasaccharide idraparinux (SanOrg 34006) with unfractinated heparin. J Thromb Haemost 2003; 09: 2054-2056.
• 5 Olson ST, Swanson R, Raub-Segall E. et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Thromb Heamost 2004; 92: 929-939.
• 6 Hoppensteadt D, Walenga J, Jeske W. et al. Lack of dose-response with Fondaparinux and Idraparinux is due to endogenous antithrombin saturation. J Thromb Haemost 2003; 07 (Suppl. 02) P2069 (Abstract).
• 7 van Gogh Investigators. Buller HR, Cohen AT. et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
• 8 van Gogh Investigators. Buller HR, Cohen AT. et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.
• 9 Buller HR, Destors JM, Gallus AS. et al. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (Equinox study): safety, efficacy and reversibility by avidin. Blood. 2008 112: Abstract 12.